1. Home
  2. SNBR vs INAB Comparison

SNBR vs INAB Comparison

Compare SNBR & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sleep Number Corporation

SNBR

Sleep Number Corporation

HOLD

Current Price

$8.57

Market Cap

186.9M

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.51

Market Cap

10.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNBR
INAB
Founded
1987
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
186.9M
10.6M
IPO Year
1998
2021

Fundamental Metrics

Financial Performance
Metric
SNBR
INAB
Price
$8.57
$1.51
Analyst Decision
Hold
Strong Buy
Analyst Count
3
2
Target Price
$8.00
$108.00
AVG Volume (30 Days)
891.0K
52.2K
Earning Date
11-05-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,440,882,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.49
$1.53
52 Week High
$20.73
$12.53

Technical Indicators

Market Signals
Indicator
SNBR
INAB
Relative Strength Index (RSI) 72.83 34.24
Support Level $7.75 $1.73
Resistance Level $8.65 $1.87
Average True Range (ATR) 0.75 0.13
MACD 0.32 -0.02
Stochastic Oscillator 97.76 8.30

Price Performance

Historical Comparison
SNBR
INAB

About SNBR Sleep Number Corporation

Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Share on Social Networks: